Login Register Cart 0
Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?

Author(s): Maliha Naseer, Shiva Poola, Syed Ali, Sami Samiullah and Veysel Tahan*

Volume 15, Issue 3, 2020

Page: [216 - 233] Pages: 18

DOI: 10.2174/1574884715666200312100237

Price: $65

Open Access Journals Promotions 2
Abstract

The incidence, prevalence, and cost of care associated with diagnosis and management of inflammatory bowel disease are on the rise. The role of gut microbiota in the causation of Crohn's disease and ulcerative colitis has not been established yet. Nevertheless, several animal models and human studies point towards the association. Targeting intestinal dysbiosis for remission induction, maintenance, and relapse prevention is an attractive treatment approach with minimal adverse effects. However, the data is still conflicting. The purpose of this article is to provide the most comprehensive and updated review on the utility of prebiotics and probiotics in the management of active Crohn’s disease and ulcerative colitis/pouchitis and their role in the remission induction, maintenance, and relapse prevention. A thorough literature review was performed on PubMed, Ovid Medline, and EMBASE using the terms “prebiotics AND ulcerative colitis”, “probiotics AND ulcerative colitis”, “prebiotics AND Crohn's disease”, “probiotics AND Crohn's disease”, “probiotics AND acute pouchitis”, “probiotics AND chronic pouchitis” and “prebiotics AND pouchitis”. Observational studies and clinical trials conducted on humans and published in the English language were included. A total of 71 clinical trials evaluating the utility of prebiotics and probiotics in the management of inflammatory bowel disease were reviewed and the findings were summarized. Most of these studies on probiotics evaluated lactobacillus, De Simone Formulation or Escherichia coli Nissle 1917 and there is some evidence supporting these agents for induction and maintenance of remission in ulcerative colitis and prevention of pouchitis relapse with minimal adverse effects. The efficacy of prebiotics such as fructooligosaccharides and Plantago ovata seeds in ulcerative colitis are inconclusive and the data regarding the utility of prebiotics in pouchitis is limited. The results of the clinical trials for remission induction and maintenance in active Crohn's disease or post-operative relapse with probiotics and prebiotics are inadequate and not very convincing. Prebiotics and probiotics are safe, effective and have great therapeutic potential. However, better designed clinical trials in the multicenter setting with a large sample and long duration of intervention are needed to identify the specific strain or combination of probiotics and prebiotics which will be more beneficial and effective in patients with inflammatory bowel disease.

Keywords: Prebiotics, probiotics, inflammatory bowel disease, Crohn’s Disease (CD), ulcerative colitis, pouchitis.

« Previous Next »
Graphical Abstract

[1]
Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
[2]
Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998; 115(1): 182-205.
[http://dx.doi.org/10.1016/S0016-5085(98)70381-6] [PMID: 9649475]
[3]
Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care 2017; 44(4): 673-92.
[http://dx.doi.org/10.1016/j.pop.2017.07.010] [PMID: 29132528]
[4]
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142(1): 46-54.
[http://dx.doi.org/10.1053/j.gastro.2011.10.001] [PMID: 22001864]
[5]
Hammer T, Nielsen KR, Munkholm P, Burisch J, Lynge E. The faroese IBD study: Incidence of inflammatory bowel diseases across 54 years of population-based data. J Crohn’s Colitis 2016; 10(8): 934-42.
[http://dx.doi.org/10.1093/ecco-jcc/jjw050] [PMID: 26933031]
[6]
Kuenzig ME, Benchimol EI, Lee L, et al. The impact of inflammatory bowel disease in Canada 2018: Direct costs and health services utilization. J Can Assoc Gastroenterol 2019; 2(Suppl. 1): S17-33.
[http://dx.doi.org/10.1093/jcag/gwy055] [PMID: 31294382]
[7]
Park KT, Ehrlich OG, Allen JI, et al. The cost of inflammatory bowel disease: An initiative from the Crohn’s & colitis foundation. Inflamm Bowel Dis 2019; 65(42): 1166.
[8]
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448(7152): 427-34.
[http://dx.doi.org/10.1038/nature06005] [PMID: 17653185]
[9]
Ko JK, Auyeung KK. Inflammatory bowel disease: Etiology, pathogenesis and current therapy. Curr Pharm Des 2014; 20(7): 1082-96.
[http://dx.doi.org/10.2174/13816128113199990416] [PMID: 23782147]
[10]
Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on therapeutics in Crohn’s disease: Medical treatment. J Crohn’s Colitis 2019.
[11]
Whelan K, Quigley EMM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29(2): 184-9.
[http://dx.doi.org/10.1097/MOG.0b013e32835d7bba] [PMID: 23286925]
[12]
Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 2017; 9(9): 1021.
[13]
Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: Current status and the future ahead. Gastroenterology 2014; 146(6): 1489-99.
[http://dx.doi.org/10.1053/j.gastro.2014.02.009] [PMID: 24560869]
[14]
Shamoon M, Martin NM, O’Brien CL. Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications. Pharmacol Res 2019; 148104344
[http://dx.doi.org/10.1016/j.phrs.2019.104344]] [PMID: 31400403]
[15]
Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: Is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol 2013; 6(1): 53-68.
[http://dx.doi.org/10.1177/1756283X12454590] [PMID: 23320050]
[16]
Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017; 474(11): 1823-36.
[http://dx.doi.org/10.1042/BCJ20160510] [PMID: 28512250]
[17]
Gu Y, Zhou G, Qin X, Huang S, Wang B, Cao H. The potential role of gut mycobiome in irritable bowel syndrome. Front Microbiol 2019; 10: 1894.
[http://dx.doi.org/10.3389/fmicb.2019.01894] [PMID: 31497000]
[18]
Yu LC-H. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: Exploring a common ground hypothesis. J Biomed Sci 2018; 25(1): 79-14.
[http://dx.doi.org/10.1186/s12929-018-0483-8] [PMID: 30253755]
[19]
Kawada M, Arihiro A, Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 2007; 13(42): 5581-93.
[http://dx.doi.org/10.3748/wjg.v13.i42.5581] [PMID: 17948932]
[20]
Sartor RB. Postoperative recurrence of Crohn’s disease: The enemy is within the fecal stream. Gastroenterology 1998; 114(2): 398-400.
[http://dx.doi.org/10.1016/S0016-5085(98)70492-5] [PMID: 9453501]
[21]
Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ 2019; 7(5)e7502
[http://dx.doi.org/10.7717/peerj.7502] [PMID: 31440436]
[22]
Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012; 4(8): 1095-119.
[http://dx.doi.org/10.3390/nu4081095] [PMID: 23016134]
[23]
Jain N, Walker WA. Diet and host-microbial crosstalk in postnatal intestinal immune homeostasis. Nat Rev Gastroenterol Hepatol 2015; 12(1): 14-25.
[http://dx.doi.org/10.1038/nrgastro.2014.153] [PMID: 25201040]
[24]
Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3(4): 213-23.
[http://dx.doi.org/10.1016/j.chom.2008.02.015] [PMID: 18407065]
[25]
Nair GB. Homeostasis and dysbiosis of the gut micro biome in health and disease. J Biosci 2019; 44(5): 117.
[26]
Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011; 17(12): 1519-28.
[http://dx.doi.org/10.3748/wjg.v17.i12.1519]] [PMID: 21472114]
[27]
Li J, Butcher J, Mack D. diseases ASIB Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel diseases. Inflamm Bowel Dis 2015; 21(1): 139-53.
[28]
Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: Friend of foe? World J Gastroenterol 2011; 17(5): 557-66.
[http://dx.doi.org/10.3748/wjg.v17.i5.557] [PMID: 21350704]
[29]
Somineni HK, Kugathasan S. The microbiome in patients with inflammatory diseases. Clin Gastroenterol Hepatol 2019; 17(2): 243-55.
[http://dx.doi.org/10.1016/j.cgh.2018.08.078] [PMID: 30196163]
[30]
Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13(6): 675-83.
[http://dx.doi.org/10.1002/ibd.20101] [PMID: 17262808]
[31]
Minot S, Sinha R, Chen J, et al. The human gut virome: Inter-individual variation and dynamic response to diet. Genome Res 2011; 21(10): 1616-25.
[http://dx.doi.org/10.1101/gr.122705.111] [PMID: 21880779]
[32]
Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut 2017; 66(6): 1039-48.
[http://dx.doi.org/10.1136/gutjnl-2015-310746] [PMID: 26843508]
[33]
Aggeletopoulou I, Konstantakis C, Assimakopoulos SF, Triantos C. The role of the gut microbiota in the treatment of inflammatory bowel diseases. Microb Pathog 2019; 137103774
[http://dx.doi.org/10.1016/j.micpath.2019.103774]] [PMID: 31586663]
[34]
Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014; 7: 473-87.
[PMID: 25525379]
[35]
Lilly DM, Stillwell RH. Probiotics: Growth-promoting factors produced by microorganismS. Science 1965; 147(3659): 747-8.
[http://dx.doi.org/10.1126/science.147.3659.747]] [PMID: 14242024]
[36]
Food and Agriculture Organization of the United Nations. 2001.https://www.who.int/foodsafety/fs_management/en/probiotic guidelines.pdf [Accessed on November 29, 2019]
[37]
Timmerman HM, Koning CJM, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies probiotics-A comparison of functionality and efficacy. Int J Food Microbiol 2004; 96(3): 219-33.
[http://dx.doi.org/10.1016/j.ijfoodmicro.2004.05.012] [PMID: 15454313]
[38]
Sherman PM, Ossa JC, Henry KJ. Unraveling Mechanisms of Action of Probiotics. Nutrition in Clinical Practice. John Wiley & Sons. Ltd 2009; 24(1): 10-4.
[39]
Hedin CRH, Mullard M, Sharratt E, et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: A case-control study. Inflamm Bowel Dis 2010; 16(12): 2099-108.
[http://dx.doi.org/10.1002/ibd.21286] [PMID: 20848469]
[40]
Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr 1995; 125(6): 1401-12.
[http://dx.doi.org/10.1093/jn/125.6.1401] [PMID: 7782892]
[41]
Steed H, Macfarlane GT, Macfarlane S. Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res 2008; 52(8): 898-905.
[http://dx.doi.org/10.1002/mnfr.200700139]
[42]
Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999; 354(9179): 635-9.
[http://dx.doi.org/10.1016/S0140-6736(98)06343-0] [PMID: 10466665]
[43]
Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010; 10(1): 13-8.
[http://dx.doi.org/10.1186/1472-6882-10-13] [PMID: 20398311]
[44]
Petersen AM, Mirsepasi H, Halkjaer SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. J Crohn’s Colitis 2014; 8(11): 1498-505.
[http://dx.doi.org/10.1016/j.crohns.2014.06.001] [PMID: 24972748]
[45]
Huynh HQ, deBruyn J, Guan L, et al. Probiotic preparation De Simone Formulation induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflamm Bowel Dis 2009; 15(5): 760-8.
[http://dx.doi.org/10.1002/ibd.20816] [PMID: 19067432]
[46]
Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004; 10(11): PI126-31.
[PMID: 15507864]
[47]
Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (De Simone Formulation) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104(2): 437-43.
[http://dx.doi.org/10.1038/ajg.2008.118] [PMID: 19174792]
[48]
Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Gos-wami P, et al. The probiotic preparation, De Simone Formulation induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7(11): 1202-9.
[http://dx.doi.org/10.1016/j.cgh.2009.07.016] [PMID: 19631292]
[49]
Ng SC, Plamondon S, Kamm MA, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 2010; 16(8): 1286-98.
[http://dx.doi.org/10.1002/ibd.21222] [PMID: 20155842]
[50]
Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic De Simone Formulation as adjunctive to a standard pharmaceuti-cal treatment: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105(10): 2218-27.
[http://dx.doi.org/10.1038/ajg.2010.218] [PMID: 20517305]
[51]
Soo I, Madsen KL, Tejpar Q, et al. De Simone Formulation probiotic upregulates intestinal mucosal alkaline sphingomye-linase and reduces inflammation. Can J Gastroenterol 2008; 22(3): 237-42.
[http://dx.doi.org/10.1155/2008/520383] [PMID: 18354751]
[52]
Tamaki H, Nakase H, Inoue S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016; 28(1): 67-74.
[http://dx.doi.org/10.1111/den.12553] [PMID: 26418574]
[53]
Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20(10): 1133-41.
[54]
Takeda Y, Nakase H, Namba K, et al. Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis. Inflamm Bowel Dis 2009; 15(11): 1617-8.
[http://dx.doi.org/10.1002/ibd.20861] [PMID: 19161180]
[55]
Li G, Zeng S, Liao WLN. The effect of bifid triple viable on immune function of patients with ulcerative colitis. Gastroenterol Res Pract 2012; 2012(4): 404752-9.
[http://dx.doi.org/10.1155/2012/404752]] [PMID: 22927836]
[56]
Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, et al. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012; 35(3): 327-34.
[57]
D’Incà R, Barollo M, Scarpa M, et al. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci 2011; 56(4): 1178-87.
[http://dx.doi.org/10.1007/s10620-010-1384-1] [PMID: 20737210]
[58]
Bjarnason I, Sission G, Hayee B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology 2019; 27(3): 465-73.
[http://dx.doi.org/10.1007/s10787-019-00595-4] [PMID: 31054010]
[59]
Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15(6): 697-8.
[http://dx.doi.org/10.1097/00042737-200306000-00017] [PMID: 12840682]
[60]
Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53(11): 1617-23.
[http://dx.doi.org/10.1136/gut.2003.037747] [PMID: 15479682]
[61]
Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11(5): 853-8.
[62]
Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13(8): 1103-8.
[http://dx.doi.org/10.1046/j.1365-2036.1999.00560.x]
[63]
Cui H-H, Chen C-L, Wang J-D, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 10(10): 1521-5.
[http://dx.doi.org/10.3748/wjg.v10.i10.1521] [PMID: 15133865]
[64]
Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohn’s Colitis 2011; 5(2): 115-21.
[http://dx.doi.org/10.1016/j.crohns.2010.11.004] [PMID: 21453880]
[65]
Matsuoka K, Uemura Y, Kanai T, et al. Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Dig Dis Sci 2018; 63(7): 1910-9.
[http://dx.doi.org/10.1007/s10620-018-4946-2]] [PMID: 29450747]
[66]
Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23(11): 1567-74.
[67]
Kanauchi O, Mitsuyama K, Homma T, et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: Multi-center open trial. Int J Mol Med 2003; 12(5): 701-4.
[http://dx.doi.org/10.3892/ijmm.12.5.701] [PMID: 14532996]
[68]
Valcheva R, Koleva P, Martínez I, Walter J, Gänzle MG, Dieleman LA. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels. Gut Microbes 2019; 10(3): 334-57.
[http://dx.doi.org/10.1080/19490976.2018.1526583] [PMID: 30395776]
[69]
Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, et al. Spanish group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol 1999; 94(2): 427-33.
[PMID: 10022641]
[70]
Hanai H, Kanauchi O, Mitsuyama K, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004; 13(5): 643-7.
[http://dx.doi.org/10.3892/ijmm.13.5.643] [PMID: 15067363]
[71]
Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991; 26(7): 747-50.
[72]
Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 46(4): 389-400.
[73]
Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea pilot study. Z Gastroenterol 1993; 31(2): 129-34.
[PMID: 8465554]
[74]
Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 1997; 25(4): 653-8.
[http://dx.doi.org/10.1097/00004836-199712000-00021] [PMID: 9451682]
[75]
Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn’s diseaseJ. Gastroenterol Hepatol 2007; 22(8): 1199-204.
[76]
Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 2004; 4(1): 5-4.
[http://dx.doi.org/10.1186/1471-230X-4-5] [PMID: 15113451]
[77]
Steed H, Macfarlane GT, Blackett KL, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther 2010; 32(7): 872-3.
[78]
Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000; 45(7): 1462-4.
[http://dx.doi.org/10.1023/A:1005588911207] [PMID: 10961730]
[79]
Zocco MA, Verme LZD, Armuzzi A, et al. Comparison of lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn’s disease. Gastroenterology Elsevier 2003; 124(4): A201.
[http://dx.doi.org/10.1016/S0016-5085(03)81006-5]
[80]
Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 2005; 11(9): 833-9.
[http://dx.doi.org/10.1097/01.MIB.0000175905.00212.2c] [PMID: 16116318]
[81]
Rutgeerts P, D’Haens G, Baert F, Van Assche G. Randomized placebo controlled trial of pro-and prebiotics (synbiotics cocktail) for maintenance of infliximab induced remission of luminal Crohn’s disease. Gastroenterology 2004; 126(4): A467-7.
[82]
Willert RP, Peddi KK, Ombiga J, Bampton PA, Lawrance IC. T1235 Randomised, Double-Blinded, Placebo-Controlled Study of De Simone formulation versus placebo in the maintenance of remission in Crohns disease. Gastroenterology Elsevier 2010; 138(5): S–517-8.
[http://dx.doi.org/10.1016/S0016-5085(10)62390-6]
[83]
Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: A randomised controlled trial with Lactobacillus GG. Gut 2002; 51(3): 405-9.
[http://dx.doi.org/10.1136/gut.51.3.405] [PMID: 12171964]
[84]
Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis 2007; 13(2): 135-42.
[http://dx.doi.org/10.1002/ibd.20063] [PMID: 17206696]
[85]
Marteau P, Lémann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: A randomised, double blind, placebo controlled GETAID trial. Gut 2006; 55(6): 842-7.
[http://dx.doi.org/10.1136/gut.2005.076604] [PMID: 16377775]
[86]
Campieri M, Rizzello F, Venturi A, Poggioli G. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease: A randomized controlled study vs. mesalazine. Gastroenterology 2000; 118: A781.
[87]
Fedorak RN, Feagan BG, Hotte N, et al. The probiotic De Simone formulation has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s dis-ease. Clin Gastroenterol Hepatol 2015; 13(5): 928-35.
[http://dx.doi.org/10.1016/j.cgh.2014.10.031] [PMID: 25460016]
[88]
Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut 2006; 55(3): 348-55.
[http://dx.doi.org/10.1136/gut.2005.074971] [PMID: 16162680]
[89]
Joossens M, De Preter V, Ballet V, Verbeke K, Rutgeerts P, Vermeire S. Effect of Oligofructose-enriched Inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn’s disease: Results from a double-blinded randomized controlled trial. Gut 2012; 61(6): 958-8.
[http://dx.doi.org/10.1136/gutjnl-2011-300413] [PMID: 21749983]
[90]
Benjamin JL, Hedin CRH, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut 2011; 60(7): 923-9.
[http://dx.doi.org/10.1136/gut.2010.232025] [PMID: 21262918]
[91]
Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bis-choff SC. Effect of oral lactulose on clinical and immuno-histochemical parameters in patients with inflammatory bowel disease: A pilot study. BMC Gastroenterol. BioMed Central 2007; 7(1): 1-11.
[http://dx.doi.org/10.1186/1471-230X-7-36] [PMID: 17784949]
[92]
Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: Complications and long-term outcome in 1310 patients. Br J Surg 1998; 85(6): 800-3.
[http://dx.doi.org/10.1046/j.1365-2168.1998.00689.x] [PMID: 9667712]
[93]
Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2019; 5(5)CD001176
[http://dx.doi.org/10.1002/14651858.CD001176.pub2]
[94]
Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. Expert Rev Gastroenterol Hepatol 2009; 3(5): 547-59.
[http://dx.doi.org/10.1586/egh.09.37] [PMID: 19817675]
[95]
Welters CFM, Heineman E, Thunnissen FBJM, van den Bogaard AEJM, Soeters PB, Baeten CGMI. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002; 45(5): 621-7.
[http://dx.doi.org/10.1007/s10350-004-6257-2] [PMID: 12004211]
[96]
Laake KO, Bjørneklett A, Bakka A, Midtvedt T, Norin KE, Eide TJ, et al. Influence of fermented milk on clinical state, fecal bacterial counts and biochemical characteristics in patients with ileal-pouch-anal-anastomosis. Microb Ecol Health Dis 2009; 11(4): 211-7.
[97]
Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2017; 27(4): 409-14.
[98]
Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 1(4): 509-15.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01465.x]
[99]
Laake KO, Line PD, Grzyb K, et al. Assessment of mucosal inflammation and blood flow in response to four weeks’ intervention with probiotics in patients operated with a J-Configurated Ileal-Pouch-Anal-Anastomosis (IPAA). Scand J Gastroenterol 2009; 8(12): 1228-35.
[100]
Laake KO, Bjørneklett A, Aamodt G, et al. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical recon-struction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol 2009; 840(1): 43-51.
[101]
Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003; 124(5): 1202-9.
[http://dx.doi.org/10.1016/S0016-5085(03)00171-9] [PMID: 12730861]
[102]
Tomasz B, Zoran S, Jarosław W, Ryszard M, Marcin G, Robert B, et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: A randomized prospective study. Int BioMed Res 2014; 21(1): 1-4.
[103]
Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50(12): 2075-82.
[http://dx.doi.org/10.1007/s10350-007-9068-4] [PMID: 17934776]
[104]
Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (De Simone Formulation) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53(1): 108-14.
[http://dx.doi.org/10.1136/gut.53.1.108] [PMID: 14684584]
[105]
Shen B, Brzezinski A. Maintenance therapy with a probiotic in antibi-otic dependent pouchitis: Experience in clinical practice Aliment Pharmacol Ther. John Wiley Sons Ltd 2005; 1(8): 721-8.
[106]
Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000; 119(2): 305-9.
[http://dx.doi.org/10.1053/gast.2000.9370] [PMID: 10930365]
[107]
Gosselink MP, Schouten WR, van Lieshout LMC, Hop WCJ, Laman JD, Embden JGHR-V. Delay of the First Onset of Pouchitis by Oral Intake of the Probiotic Strain Lactobacillus rhamnosus GGDis Colon Rectum. Springer-Verlag 2004; pp. 876-4.
[http://dx.doi.org/10.1007/s10350-004-0525-z]
[108]
Pronio A, Montesani C. Probiotic administration in patients with ileal pouch–anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008; 14(5): 662-8.
[109]
Yasueda A, Mizushima T, Nezu R, et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis Surg Today. 2nd ed. Japan: Springer 2015; pp. 939-49.
[110]
McLaughlin SD, Johnson MW, Clark SK, Tekkis PP, Ciclitira PJ, Nicholls RJ. W1767 De Simone Formulation for Chronic Pouchitis; Experience in UK Clinical. Practice Gastroenterology 2008; 134(4): A-711.
[http://dx.doi.org/10.1016/S0016-5085(08)63321-1]
[111]
Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis 2015.
[http://dx.doi.org/10.1002/14651858.CD001176.pub3]

Rights & Permissions Print Cite
Article Metrics
121
3
© 2024 Bentham Science Publishers | Privacy Policy